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Role of glucocorticoid in excretion of an acute potassium load in
patients with Addison's disease and panhypopitultarism. Glucocorticoid
(GC) has been shown to stimulate potassium (K) excretion in various
conditions, but it is still incompletely resolved whether its presence is
essential for the normal K homeostasis. We addressed this question in
patients with selective GC deficiency (panhypopituitarism) and with
combined GC and mineralocorticoid deficiency (Addison's disease),
studied 24 hours after withdrawal of their regular substitution therapy.
Compared to data in healthy subjects, both basal K excretion and the
kaliuresis after a KCI load (I mmollkg body wt orally) were impaired in
either patient group (P < 0.05). Physiological cortisol supplementation(20 mg 3 hr prior to test, and 1 mg/hr during test) increased basal K
excretion (from 10.6 1.8 to 19.2 1.9 mmol/5 hr, P < 0.01) and KCI
stimulated kaliuresis (from 47.9 6.1 to 54.8 4.7 mmolI5 hr, P = 0.06)
to normal levels in panhypopituitarism. Cortisol also improved basal K
excretion (from 10.2 1.5 to 16.9 3.5 mmol/5 hr, P < 0.05) and
KCI-stimulated K excretion (from 31.6 2.5 to 45.2 3.8 mmolJ5 hr,
P < 0.05) in Addison's disease, although KCI-stimulated K excretion
remained below normal (P < 0.01). The effects of cortisol on sodium
excretion differed between the two patient groups (P < 0.05) in that
only in Addison's disease the improved K excretion was associated
with sodium retention. Additional experiments with the purely GC
compound dexamethasone (0.5 mg 3 hr prior to test, and 0.03 mg/hr
during test) in the patients with Addison's disease also improved K
excretion (P < 0.05), but without the concomitant sodium retention
observed after cortisol. These data speak for a physiological role of GC
in potassium homeostasis, and also suggest that cortisol, as the impor-
tant endogenous GC hormone, has mineralocorticoid-like effects spe-
cifically in the absence of aldosterone.
Both acute and chronic administration of glucocorticoids
have been found to increase potassium excretion in healthy
subjects [1—5], in occasional patients with adrenal insufficiency
[1, 6], as well as in adrenalectomized animals [7—12]. Sometimes
the glucocorticoid-induced kaliuresis has been even greater
than the kaliuresis after mineralocorticoid administration [1, 3,
6, 9—111. Furthermore, it has been demonstrated that in adre-
nalectomized rats the excretion of a potassium load is signifi-
cantly improved by replacement of glucocorticoid [7, 8, 11, 12].
These observations have led to the assumption that glucocorti-
colds play a part in the regulation of potassium homeostasis.
Nonetheless, it is unresolved if and to what extent glucocor-
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ticoids are required for normal K homeostasis. In previous
studies in glucocorticoid deficient situations, often supraphysi-
ological dosages or steroids with mixed gluco- and mineralocor-
ticoid properties were employed. Acknowledging this difficulty,
Stanton et al [12] performed a series of experiments in rats
designed to reveal the separate roles of mineralocorticoid and
glucocorticoid in the renal excretion of a potassium load. A KC1
load was presented to adrenalectomized rats put on sustained
supplementation of either aldosterone, dexamethasone, both
steroids in combination, or this combination with additional
acute aldosterone together with the KC1 load. A normal kali-
uresis was seen only in the last situation, and the authors
proposed that for the normal excretion of a potassium load the
presence of both steroids, as well as acute aldosterone stimu-
lation upon the potassium load, are required for normal potas-
slum homeostasis [121. However, a group with chronic plus
acute aldosterone replacement, but without glucocorticoid re-
placement, was not included. Later, Adam, Goland and
Wellard [7] found that acute aldosterone administration alone
fully abolished the impairment of excretion of a potassium load
in adrenalectomized rats, but the dosage was very high.
Therefore, the question whether in adrenal insufficiency
physiological glucocorticoid supplementation is needed to nor-
malize potassium homeostasis is still incompletely answered.
This seems no unreasonable question, since we found recently
that the selective glucocorticoid antagonist RU486 does not
impair the excretion of a potassium load in healthy subjects
[13]. Moreover, patients with selective glucocorticoid defi-
ciency (panhypopituitarism) are not characterized by hyperkal-
emia [14], in contrast to patients with combined gluco- and
mineralocorticoid deficiency (Addison's disease) [15]. In the
former condition aldosterone production and its stimulation
upon a potassium load should be undisturbed, and it is unknown
whether the excretion of a potassium load is disturbed and
improved by physiological glucocorticoid supplementation. Re-
garding Addison's disease, our information on the effect of
glucocorticoid supplementation on potassium homeostasis is
limited to occasional patients [1, 6] and far from complete.
To further evaluate the physiological role of glucocorticoid in
the regulation of potassium excretion, we studied the response
to a standardized KC1 load in patients with panhypopituitarism
and patients with Addison's disease with and without glucocor-
ticoid replacement therapy. The results were compared with the
response to KC1 loads in healthy subjects.
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Methods
Subjects
Studies were carried out in six patients with panhypopituitar-
ism (4 males, 2 females), age range 20 to 65 years, and in seven
patients with Addison's disease (3 males, 4 females), age range
35 to 72 years. The patients with panhypopituitarism had all
undergone anterior hypophysectomy for hypophysial adeno-
mas. Addison's disease was in one patient due to tuberculosis,
and in the other six cases to auto-immune adrenalitis. All
patients were stable on chronic standard supplementation ther-
apy, and had no other disease or medication. The data were
compared to data of 14 healthy volunteers (11 males, 3 females;
age range 21 to 30 years) obtained in previous studies [13, 16].
Informed consent was obtained, and the studies were approved
by the Hospital Ethical Committee for Studies in Humans.
Study protocol in the patients
The study was primarily divided into two periods of eight
days, with an interval of two to eight weeks. During the study
periods the patients were instructed to maintain a diet contain-
ing 130 to 150 mmol Na and 80 mmol K. Clearance studies were
performed on day 5 and on day 8 of each period (see below). All
patients were on a regimen of cortisol twice daily (hydrocorti-
sone acetate 10 to 15 mg b.i.d.). For the clearance experiments
without cortisol substitution, the cortisol regimen was inter-
rupted 24 hours prior to the clearance experiments. The patients
with Addison's disease took, in addition, 1/16 mg 9a-fludrocorti-
sone twice daily; this supplementation was interrupted 24 hours
prior to all clearance studies. Additional supplementations in
the patients with panhypopituitarism (thyroxine and testoster-
one in the male subjects, and thyroxine and estrogen in the
female subjects in once daily regimens) were continued
throughout the study periods.
The clearance studies were performed after an overnight fast,
with the patient in the supine position. Antecubital veins were
catheterized bilaterally for blood sampling and infusion. A
constant infusion of inulin was started at 8 a.m., preceded by a
priming dose. After about 60 minutes equilibration, hourly urine
collections were made during a period of six hours. Blood
samples were taken at the midpoint of each hour. The patients
drank 200 ml water per hour to assure adequate urine flow
throughout the clearance study.
Each patient underwent four clearance experiments: (a) one
time control experiment without cortisol supplementation; (b)
one time control experiment in which cortisol was supple-
mented; (c) one experiment in which a KC1 load was given; (d)
one experiment during which both cortisol was supplemented
and a KCI load was administered. These experiments were
carried out in random order. The KCI load (1 mmol/kg body wt,
dissolved in 200 ml water) was administered in a single oral dose
after the first hourly urine collection. Cortisol was supple-
mented by giving 20 mg orally at 6 a.m., and a hydrocortisone
infusion at rate of 1 mglhr running from 9 a.m. until the end of
the clearance experiment. These dosages were chosen to pro-
vide physiological plasma cortisol levels of 0.2 to 0.3 mol/liter
throughout the clearance study.
Based on the outcome of the experiments (Results and
Discussion) we decided to do two additional clearance experi-
ments in the patients with Addison's disease. These experi-
ments had the same design as described above, except that
during one experiment dexamethasone was given, and in the
other experiment dexamethasone and a KC1 load were given.
Dexamethasone was chosen since this is a pure glucocorticoid
compound, with virtually no binding to mineralocorticoid re-
ceptors [17, 18]. The dosage (0.5 mg orally at 6 a.m., and 0.03
mg/hr infusion throughout the clearance experiments) was
chosen to provide a similar glucocorticoid effect as obtained by
cortisol in the preceding experiments [19].
Study protocol in the healthy control subjects
These subjects underwent two clearance studies under simi-
lar dietary conditions as the patients. One study was used as
time-control study, and in the other study a single oral dose of
KC1 (1 mmollkg body weight) was administered. The design of
the clearance experiments was equal to that in the patients. The
healthy subjects were selected to have approximately similar
body weights as the patients. As a consequence the total dose of
KC1 was comparable with that in the patients, which enabled us
to compare cumulative potassium excretions between the
groups.
Laboratory methods
Each blood and urine sample was analyzed for sodium and
potassium (Instrumentation Laboratory Autocal 743 Flame
Photometer), and inulin. Inulin was hydrolyzed to fructose and
determined photometrically with indolacetic acid. Blood sam-
ples were also analyzed for aldosterone, plasma renin activity
and cortisol employing standard radioimmunoassays.
Data analysis
Values are given as means standard error. Plasma aldoste-
rone concentrations and plasma renin activity were averaged
after logarithmic transformation. Differences in baseline data
before the clearance studies were analyzed by one-way analysis
of variance (ANOVA1R). Statistical analysis of the differences
in clearance data between the experiments with and without
glucocorticoid supplementation was performed by two-way
ANOVA for repeated measurements (ANOVA2R2). If the
variance ratio reached statistical significance, the differences
were analyzed at 5% and 1% significance level by the method of
the least significance difference. Student's r-test for paired
samples was used for comparison of cumulative electrolyte
excretions between time control and KC1 load study, and
between the studies with and without glucocorticoid replace-
ment, and for comparison of the KCI induced changes within
individuals. For comparison between the two patient groups
and control subjects the two-tailed Student's t-test for unpaired
samples was used.
Results
Twenty-four hour electrolyte excretions and body weight
prior to the clearance studies are given in Table 1. The patients
with panhypopituitarism showed adequate balance on the diet.
The patients with Addison's disease appeared to be in a
somewhat negative sodium balance, probably reflecting the fact
that they skipped their regular dosage of 9a-fludrocortisone
during this collection period. Within the patient groups, there
were no significant differences among these baseline 24 hour
data. Basal plasma electrolyte concentrations, averaged for the
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Table 1. Twenty-four hour electrolyte excretions and body weight prior to the clearance studies
Panhypopituitarism
Time control
Time control
KCI load + cortisol
KCI load +
cortisol
UNaV, mmol/24 hr 139.8 9.7 126.8 9.4 130.2 17.0 132.5 6.7
UKV, mmol/24 hr 77.5 10.4 82.8 7.5 82.5 7.2 89.0 8.2
UcrV, mmol/24 hr 12.4 1.5 12.4 1.2 11.9 1.4 11.8 1.4
Body weight, kg 76.2 7.0 76.3 7.2 76.5 7.5 76.6 7.3
Addison's disease
Time control KCI load
Time control KCI load + Time control
+ cortisol cortisol + dexa
KCI load +
dexa
UNaV, mmol/24 hr 187.9 17.3 204.4 17.9 204.7 19.7 188.6 12.8 166.3 16.0 191.3 26.3
UKV, mmol/24 hr 59.9 7.5 71.3 8.2 60.3 3.8 66.9 4.6 75.5 7.8 79.3 5.7
UrV, mmol/24 hr 10.8 0.8 11.8 0.9 11,2 0.9 11.2 0.7 10.8 0.8 12.5 1.2
Body weight, kg 73.0 2.9 72.9 3.0 73.2 3.3 73.0 3.1 72.8 2.7 72.9 2.7
Abbreviations are: UNaV, urinary sodium excretion; UKV, urinary potassium excretion; UcrV, urinary creatinine excretion; Dexa, dexameth-
asone. No significant differences appeared between different days within groups.
Panhypopituitarism Addison's disease
No With No With
cortisol cortisol cortisol cortisol
Sodium mmol/ 139 2 140 1 136 1 138 I
liter
Potassium 3.9 1.0 4.2 0.2 4.1 0.1 4.3 02
mmol/liter
Bicarbonate 24.3 1.0 25.6 0,8 23.3 0.8 23.5 1.0
mmol/liter
Chloride 97 1 100 1 97 1 102 I
mmol/liter
two tests with cortisol supplementation and the two tests
without cortisol supplementation, are presented in Table 2.
Values were within normal limits and not different in the
situations without and with cortisol replacement.
Patients with panhypopituitarism
Potassium excretion throughout the time control study (=
basal potassium excretion) increased by cortisol substitution
(Fig. 1), so that cumulative excretion over the final five hours of
this period doubled (Table 3). Cortisol also tended to increase
urine sodium excretion, plasma potassium (Fig. 2), and urine
flow (Table 4), but these changes were not significant. Cumu-
lative five hour excretion of sodium plus potassium [Table 3,
U(Na+K)VI was increased during cortisol. Plasma aldosterone
and inulin clearance remained unaffected. Plasma cortisol was
very low or below detection limits in most patients in the
absence of cortisol supplementation, and stably within the
physiological range throughout the clearance study upon corti-
sol supplementation (average value 0.22 0.02 tmolIliter).
The KCI load significantly stimulated urine potassium and
sodium excretion, and increased plasma potassium and aldoste-
rone (P < 0.01 for each item). During cortisol supplementation,
the KC1-stimulated potassium excretion was at several time
points greater than in the absence of cortisol substitution (Fig.
1), but the cumulative five-hour potassium excretions with and
without cortisol were hardly different (P = 0.06). The natriure-
0
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Fig. 1. Urinary sodium and potassium excretions in patients with
panhypopituitarism during time control (A) and KG! load (B) experi-
ments, without cortiso! substitution (—0--), and with cortisol substitu-
lion (—S—). The data concern mean excretion rates over the previous
collection hour. Ingestion of the KCI load is indicated by the arrow. * P
<0.05, compared to the study without cortisol substitution.
sis following the KC1 load was not affected by cortisol substi-
tution.
To evaluate the effects of hormone supplementation on the
magnitude of the responses to KC1, we also calculated the
changes in plasma potassium and aldosterone, and in urine
potassium and sodium excretion at two hours after the KCI load
(Table 5). At this time point peak changes had been obtained for
each variable in virtually all experiments, in patients as well as
Table 2. Baseline plasma electrolytes in the patients with and
without cortisol supplementation
A Time control B K load
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UNaV,
mmol/5 hr
UKV,
mmol/5 hr
U(Na+K)V,
mmolI5 hr
Panhypopituitarism
Time control 49.8 7.6 10.6 1.8 60.4 8.6
Time control + 57.5 6,6 19.2 19b 76.8 7,30
cortisol
KCI toad 79.9 12.7c 47.9 6.1 127.8 l6.8c
KCI load + 80.7 9.8c 54.8 4,7C 135.5 13.6c
cortisol
Addison's disease
Time control 46.1 6.5 10.2 1.5 56.2 7.2
Time control + 42.1 2.3 16.9 350 59.1 6.6
cortisol
Time control + 59.2 64d 20.8 3.00 80.0 87ad
dexa
KCI load 98.9 6.30 31.6 2.5 130.5 8.1
KCI load + 79.5 9.2 45.2 3.8a0 124.7 10.5c
cortisol
KCI load + dexa 100.4 9.6 37.7 24d 138.1 11.10
Abbreviations: UNaV, urinary sodium excretion; UKV, urinary po-
tassium excretion; U(NO+K)V, urinary sodium and potassium excretion;
Dexa, dexamethasone.
0p <0.05; bp < 0.01, compared to similar study without steroid
substitution
P < 0.01, compared to corresponding time control study
d p < 0.05, compared to similar study with cortisol substitution
normal subjects (see below), with slight further changes in only
a few cases. In the patients with panhypopituitarism the in-
crease in potassium and sodium excretion was not changed by
cortisol. Cortisol tended to increase plasma potassium (Fig. 2),
but did not influence the KC1 induced increase in plasma
potassium concentration (Table 5). The increase in plasma
aldosterone upon the KCI load was significantly greater than
without cortisol (Fig. 2, Table 5). The tendency to increase
inulin clearance was not significant.
Patients with Addison's disease
In these patients as well, basal cumulative potassium excre-
tion increased during cortisol supplementation (Table 3). Cor-
tisol tended to decrease cumulative sodium excretion and to
increase plasma potassium throughout the time control study
(Fig. 3). Plasma aldosterone was low and unaffected by cortisol.
Inulin clearance and urine flow were also unchanged (Table 4).
Plasma cortisol was below detection limits in the absence of
cortisol replacement, and within the physiological range during
replacement (average value 0.27 0.03 smol/liter).
Dexamethasone also increased basal potassium excretion,
while tending to increase sodium excretion (Fig. 3, Table 3).
Compared to the effects of cortisol, sodium excretion was
significantly higher during dexamethasone, and cumulative
[U(NO÷K)V] increased. Plasma potassium was increased signif-
icantly during dexamethasone. Plasma aldosterone, inulin
clearance and urine flow were not affected by dexamethasone.
Plasma cortisol was below detection limits in this experiment.
The KCI load consistently stimulated potassium and sodium
excretion, and increased plasma potassium (P < 0.01 for each
item), whereas plasma aldosterone remained unresponsive
(Figs. 3 and 4). Cortisol supplementation increased the KC1
stimulated kaliuresis and attenuated the natriuresis at most time
points (Fig. 3), resulting in significantly greater cumulative
012345 012345
Time, hours
Fig. 2. Plasma potassium and plasma aldosterone concentrations in
patients with panhypopituitarism during time control (A) and KCI load
(B) experiments, without corliso! substitution (—0—), and with cortisol
substitution (——), The data represent means of blood samples taken at
the midpoint of each collection hour. Ingestion of the KC1 load is
indicated by the arrow. * P < 0.05, compared to the study without
cortisol substitution.
five-hour potassium excretion and a significantly smaller cumu-
lative five-hour sodium excretion, with unchanged cumulative
[U(Na±K)Vl excretion (Table 3). The increase in potassium
excretion was enhanced by cortisol, whereas the increase in
sodium excretion was attenuated. Again, there was some ten-
dency for an elevated plasma potassium (Fig. 4), but the KCI
induced increase was not changed by cortisol (Table 5). Cortisol
had no influence on inulin clearance and urine flow (Table 4).
Dexamethasone also increased the KC1 induced kaliuresis,
but to a significantly lesser extent than cortisol (Fig. 4, Table 3).
In contrast to cortisol, dexamethasone did not affect the cumu-
lative five-hour natriuresis generated by the KCI load. Absolute
increments of sodium and potassium excretion generated by the
KCI load were not affected significantly by dexamethasone. The
increase in plasma potassium following the KCI load was
significantly stimulated (Fig. 4, Table 5), whereas inulin clear-
ance and urine flow again remained unaffected.
Comparison of data in patients and healthy volunteers
The data in the patients were compared with those collected
in healthy subjects, in whom the excretion of 1 mmol/kg body
weight KC1 loads and time control data were recorded in
previous studies [13, 161. Mean 24-hour sodium and potassium
excretions of these healthy control subjects were, respectively,
128 10 and 76 5 mmol/day on the days prior to time control
experiments, and 126 9 and 74 4 mmol/day on the days
Table 3. Cumulative electrolyte excretions A Time control B K load
+
Q2'2'2'2'2
0
E
E
E
(0
Co
00
E
Co
0
a)
I
6.5
5.5
4.5
3.5
600
400
200
0
I.-
.q)
0
E
E
(0
Cl)
00.
E
Co
0
L.
a)
E
a).
ci)C0
a)
CO00
E
Co
cci0
+*
k *
,; \A//\\T '10 *V .
1134 van Buren et al: Glucocorticoids and K excretion
Table 4. Inulin clearance and urine flow
Panhypopituitarism Addison's disease
Baseline 2nd test hour Baseline 2nd test hour
C1,,, mi/mm
Time control 76.3 9.7 81.8 15.5 77.4 9.5 82,3 9.1
Time control + cortisol 86.4 8.9 81.1 9.5 73.9 10.8 74.7 9.3
Time control + dexa 71.3 8.7 70.2 6.8
KCI load 74.7 9.1 77.2 10.8 78.3 3.7 77.1 5.6
KCI load + cortisol 89.9 11.1 89.1 7.4 76.6 10.9 78.4 9.3
KCI load + dexa 77.4 8.2 78.5 8.0
Urine flow, mi/mm
Time control 3.0 0.7 3.4 0.8 2.9 0.5 4.2 0.5
Time control + cortisol 3.8 0.8 4.6 0.8 4.0 1.0 3.1 0.8
Time control + dexa 3.9 0.6 3.7 0.4
KC1 load 2.8 1.0 4.4 0.9 3.7 0.7 5.2 0.9
KCI load + cortisol 3.2 0.6 5.4 0.8 4.4 0.5 3.6 0.5
KC1 load + dexa 3.6 0.6 5.1 0.8
Abbreviations are: C1,,, inulin clearance. Baseline and second test hour refer to the first and second collection hour of each clearance study.
Second test hours are given since in this period the effects of the KCI load on electrolyte excretions were the greatest. No significant differences
were noted between the studies within or between the patient groups.
Table 5. Change in plasma potassium and aldosterone, and in urine potassium and sodium excretion at two hours after the KC1 load
Panhypopituitarism Addison's disease
No cortjsol With cortisol No cortisol With cortisol Dexamethasone Controls
Plasma K mmol/liter 1.1 0.3 1.2 0.1 1.4 0.l 1.6 0•2b 2.2 0.2tc 0.9 0.1
Plasma aldosterone % 142 28 224 26 0 12b —15 7b 5 l5l 115 18
UKV xmo1/min 160.7 39.7 161.1 27.7 94.7 l5.4' 130.0 23.4 112.8 232b 212.2 13.5
UNaV mo1/min 303.6 51.2 322.1 48.7 281.9 50.2 215.2 49.6 242.4 56.0 277.9 23.0
Abbreviations are: UKV, urine K excretion; UNaV, urine Na excretion.
a p < 0.05, b P < 0.01 compared to control subjects
P < 0.05 compared to KC1 load without cortisol
prior to the KC1 load. Their body weights averaged, respec-
tively, 75.5 2.2 and 75.3 2.2 kg on these days. Average
body weights in the patient groups and these control subjects
were quite alike, implying that the potassium loads were also
comparable.
As reported previously [13, 16], the KCI load given to these
healthy control subjects induced transient increments of plasma
potassium and aldosterone, and of urine potassium and sodium
excretion over a period of about five hours. For each of these
variables peak increments occurred in the second hour after the
KC1 load, that is from 3.9 0.1 to 4.8 0.1 mmol/liter for
plasma potassium, from 266 31 to 518 27 pmollliter for
plasma aldosterone, from 112 12 to 390 27 tmolJmin for
urine sodium excretion, and from 94 12 to 306 15 mol/min
for urine potassium excretion (P < 0.01 for each item).
Compared to this normal response to a KC1 load, the effects
in the patients with panhypopituitarism were not significantly
different (Table 5). Upon cortisol supplementation the KC1
induced stimulation of plasma aldosterone was enhanced. In the
patients with Addison's disease, the increase in plasma potas-
sium following KC1 was greater than normal, whereas the
increase in potassium excretion was clearly below normal. As
mentioned, plasma aldosterone appeared not responsive. With
cortisol or dexamethasone these differences remained.
We also compared net five-hour potassium excretion in
patients and healthy control subjects (Fig. 5). Basal potassium
excretion was clearly suppressed in the patients with panhy-
popituitarism, and normalized by cortisol supplementation.
After the KCI load, the potassium excretion in these patients
was also less than normal, but not significantly different from
normal during cortisol replacement. Basal cumulative five-hour
potassium excretion was also suppressed in the patients with
Addison's disease, and normalized by both cortisol and dexa-
methasone. KCI-stimulated potassium excretion was also mark-
edly attenuated, and did not attain the normal level after
administration of either cortisol or dexamethasone.
In several respects the effects of cortisol in the patients with
Addison's disease differed from those in the patients with
panhypopituitarism. First, the stimulation of basal potassium
excretion was associated with a tendency for sodium excretion
in the patients with panhypopituitansm and with a tendency for
sodium retention in the patients with Addison's disease (Table
3). Although neither of these effects was significant by itself, the
difference in this response of sodium excretion was significant
between the two patient groups (P < 0.05). Second, the
increase in kaliuretic effect of KC1 caused by cortisol was twice
as large in the patients with Addison's disease (P < 0.05).
Third, this response was associated with attenuation of natri-
uresis in the patients with Addison's disease but not in the
patients with panhypopituitarism (P < 0.05).
Discussion
The present study shows that physiological supplementation
of cortisol improves basal as well as KC1-stimulated potassium
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excretion in patients with Addison's disease and in patients
with panhypopituitarism. This stresses the importance of endo-
genous glucocorticoids for potassium homeostasis, both in the
presence as in the absence of a normally functioning aldoste-
rone system.
In the patients with panhypopituitarism, the excretion of the
potassium load was only modestly impaired, and the excretion
took place at normal levels of plasma potassium. Nonetheless,
supplementation of cortisol to physiological levels improved
basal potassium excretion, and, to some extent, the kaliuresis
following the KC1 load. In the patients with Addison's disease,
the excretion of the KCI load appeared more seriously im-
paired, and took place at elevated levels of plasma potassium.
In these patients cortisol supplementation, although clearly
improving both basal and KC1-stimulated potassium excretion,
could not normalize the kaliuretic response to the KCI load.
The latter differs from patients with panhypopituitarism, and
clearly demonstrates the separate role of aldosterone in potas-
sium homeostasis. We are not aware of previous studies com-
paring the effect of cortisol on the elimination of a potassium
load in these pathophysiologically distinct patient groups.
A possible role for glucocorticoids in potassium homeostasis
has emerged from several studies in adrenalectomized rats,
showing that dexamethasone improves excretion of a potassium
load [7—10, 12]. However, the amounts given often represented
supraphysiological glucocorticoid activity. In one study, phys-
iological supplementation of glucocorticoid improved the excre-
tion of a potassium load in adrenalectomized rats, but even
combined chronic glucocorticoid and mineralocorticoid supple-
mentation could not fully restore potassium homeostasis [12].
Only after additional aldosterone supplementation together
with the KC1 load did the excretion of this potassium load
became normal [12]. These data elegantly show the importance
of an intact, responsive aldosterone system for the excretion of
a potassium load, but remain inconclusive with respect to the
role of glucocorticoid, since a group with chronic and acute
aldosterone supplementation in the absence of glucocorticoid
supplementation was not included. In our study, such a group is
represented by the patients with panhypopituitarism, having a
normally responsive aldosterone system, while lacking cortisol.
The present data leave no doubt that in such conditions
physiological glucocorticoid replacement improves the excre-
tion of a potassium load, even though the disturbance in
potassium homeostasis is only modest [14].
How cortisol can increase potassium excretion is only par-
tially clear. Glucocorticoids, in contrast to mineralocorticoids,
have no direct effect on potassium and sodium transport in the
distal tubule or cortical collecting tubule [10, 20, 21], but
probably stimulate potassium secretion by increasing distal
sodium and water delivery [12, 22]. Increased glomerular filtra-
tion may participate in this event [9, 23]. Accordingly, im-
proved potassium excretion by physiological substitution of
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Fig. 4. Plasma potassium and aldosterone concentrations in patients
with Addison's disease during time control (A) and KCI load (B)
experiments, without cortisol substitution (—0—), with corrisol substitu-
tion (—-), and with dexamethasone substitution (—is—). The data
represent means of blood samples taken at the midpoint of each
collection hour. Ingestion of the KC1 load is indicated by the arrow. * P
< 0.05, ** P < 0.01, compared to the study without cortisol
substitution.
Time, hours
Fig. 3. Urinary sodium and potassium excretions in patients with
Addison's disease during time control (A) and KCI load (B) experi-
ments, without cortisol substitution (—0—), with cortisol substitution
(——), and with dexamethasone substitution (—Lx—). Data concern mean
excretion rates over the previous collection hour. Ingestion of the KCI
load is indicated by the arrow. * P < 0.05, ** P < 0.01, compared to
the study without cortisol substitution; *P < 0.05, ** P < 0.01,
compared to the study with dexamethasone substitution.
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Time control KCI load
Fig. 5. Cumulative potassium excretion in patients with panhypopitu-
itarism (PHP) and Addison's disease (ADD) compared to normal
subjects (N), during time control and KC1 load experiments. Symbols
are: () no steroid; (U) cortisol; (0) dexamethasone. *P <0.05, ** P
<0.01, compared to potassium excretion in the normal subjects.
glucocorticoid in adrenalectomized rats is associated with un-
changed or increased sodium excretion [8, 9, 12, 24, 25]. By
contrast, the improved potassium excretion by substitution of
mineralocorticoid is accompanied by sodium retention [8, 9, 12,
25], since mineralocorticoids increase sodium reabsorption in
the distal nephron in favor of potassium secretion [26, 27]. In
this respect it is interesting to compare the effects in the two
patient groups. Although cortisol supplementation increased
basal potassium excretion in both groups, it tended to reduce
sodium excretion in the patients with Addison's disease and to
increase sodium excretion in the patients with panhypopituitar-
ism. This difference in urinary sodium response between the
two patient groups was significant. Also, the stimulation of KCI
induced kaliuresis was accompanied by complementary re-
duced natriuretic response in the patients with Addison's dis-
ease, resulting in unchanged cumulative [Na+KJ excretion, but
with unchanged natriuretic response in the patients with pan-
hypopituitarism. Following from the above, these different
responses suggest that the effect of cortisol was glucocorticoid-
like in the patients with panhypopituitarism, whereas that in the
patients with Addison's disease resembled a mineralocorticoid-
like effect.
In the patients with panhypopituitarism cortisol shifted both
basal and KC1-stimulated potassium excretion curves upwards,
but had no effect on the actual increase in potassium excretion
caused by the KC1 load. This could mean that cortisol improves
potassium excretion through a more or less consistent elevation
of distal delivery, but has no influence on the further modula-
tion of this distal delivery, In the patients with Addison's
disease, however, cortisol enhanced the actual increase in
potassium excretion induced by the KC1 load, while attenuating
the natriuretic response. This would also agree with a miner-
alocorticoid type of effect, since this suggests that cortisol
modulated the handling rather than the rate of distal delivery.
Why cortisol should have mineralocorticoid-type effects spe-
cifically in patients with Addison's disease is not directly
apparent. Binding of cortisol to renal mineralocorticoid recep-
tors is probably very low in vivo [28—30]. Perhaps, in the
absence the natural mineralocorticoid aldosterone, increased
mineralocorticoid receptor availability promotes the binding of
cortisol. However, the low mineralocorticoid-receptor binding
capacity of cortisol is probably due to intrarenal degradation of
cortisol by 1 1/3-hydroxysteroid dehydrogenase [28—30], and it is
not known whether this degradation is suppressed in aldoste-
rone deficiency. Another option is that cortisol has mineralo-
corticoid-like effects through activation of a non-mineralocorti-
coid receptor. The existence of such receptors has been
demonstrated recently in cultured rabbit collecting tubule cells
[31]. In humans, the antinatriuretic effects of cortisol could not
be inhibited by selective glucocorticoid or mineralocorticoid
receptor blockade [4, 5]. However, these studies dealt with
stress amounts of cortisol, and may therefore not apply to our
findings. Moreover, it is unclear why the expression of such an
effect would be more pronounced in the absence of aldosterone.
To further discriminate whether the beneficial effect of cor-
tisol supplementation on potassium excretion in glucocorticoid
deficiency depends upon glucocorticoid receptor stimulation,
we performed additional experiments with dexamethasone.
This was done only to the patients with Addison's disease, the
group which had responded to cortisol with a mineralocorti-
coid-type rather than a glucocorticoid-type of effect. It ap-
peared that dexamethasone, in a dosage of about equal glu-
cocorticoid potency compared to the dosage of cortisol, again
increased both basal and KC1-stimulated potassium excretion,
although the latter to a somewhat lesser extent, and without the
simultaneous suppression of sodium excretion as observed after
cortisol. It is therefore likely that physiological stimulation of
glucocorticoid receptors indeed contributes to potassium ho-
meostasis. The difference between dexamethasone and cortisol
may be explained by additional non-glucocorticoid receptor
stimulation by the latter compound.
Plasma potassium, specifically the prompt increments in
plasma potassium following a KCI load, is probably a major
factor in mediating renal potassium excretion [10, 16], and
merits attention for several reasons. A striking observation was
that both cortisol and dexamethasone tended to increase plasma
potassium. Although often not significant, this tendency was
found throughout our experiments. In view of the potent
influence of plasma potassium on tubular potassium secretion
[10, 32], we cannot exclude that even these subtle changes in
plasma potassium contributed to the kaliuretic effect of glu-
cocorticoid supplementation. The slight hyperkalemic effect
may also have contributed to the enhanced KCI-induced in-
crease in aldosterone observed in the patients with panhypo-
pituitarism [33]. In contrast to our data, however, physiological
glucocorticoid replacement does not appear to increase plasma
potassium in adrenalectomized rats [8, 9, 12, 241, and the
kaliuretic effect observed in these animals is therefore indepen-
dent of changes in plasma potassium. In dogs, hyperkalemia
following adrenalectomy was even found to improve after
cortisone, even though this had little kaliuretic effect [34]. Data
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in humans are scarce. Transient increments in plasma potas-
sium of as much as 0.5 to 1.0 mmollliter after single pharmaco-
logical doses of glucocorticoid to healthy volunteers have been
reported in early studies [1, 2, 35]. However, the mechanism by
which glucocorticoids might influence extrarenal potassium
distribution is unclear [361. It seems unlikely that increments in
plasma glucose, which are minor even after stress dosages of
cortisol [4], would be sufficient explanation.
Basal plasma potassium in the patients with Addison's dis-
ease, although clearly aldosterone deficient and characterized
by impaired potassium excretion, was not elevated. However,
since the final dose of fludrocortisone was taken only 24 hours
prior, the actual mineralocorticoid deficiency had lasted only
for a short period, and the positive potassium balance, esti-
mated from the 24-hour potassium excretion, amounted to 10 to
20 mmoles at most. More prolonged potassium retention is
probably required to cause hyperkalemia, which by itself im-
proves potassium excretion [10, 16, 32] and thus would com-
plicate interpretation of our data. On the other hand, the rise in
plasma potassium upon the KC1 load was most pronounced in
these patients. This undoubtedly reflects the deficiency of
aldosterone, which plays an important role in extrarenal potas-
sium disposal [36, 37]. Impaired potassium excretion despite
enhanced increase in plasma potassium further emphasizes the
potassium excretory defect in these patients with Addison's
disease.
The present data contrast with our recent finding that RU486,
a glucocorticoid-receptor antagonist, does not impair the excre-
tion of a potassium load in healthy humans [13]. The reason for
the discrepancy is not fully clear. Possibly, the absence of
endogenous glucocorticoid in the presently studied patients was
more complete than was simulated by the single dose of RU486
applied in the healthy subjects of our previous study [13].
In summary, physiological glucocorticoid supplementation in
glucocorticoid deficient patients improves both basal potassium
excretion and the excretion of a potassium load. This empha-
sizes the role of glucocorticoid in potassium homeostasis. Our
findings also suggest that in patients with combined glucocorti-
coid and mineralocorticoid deficiency, the kaliuretic effect of
cortisol is at least partly due to a mineralocorticoid-like action.
This implies that cortisol, the main endogenous glucocorticoid
hormone, specifically exerts mineralocorticoid-like effects if
mineralocorticoids are absent. Finally, physiological replace-
ment of cortisol causes subtle increments in plasma potassium,
which may contribute to its kaliuretic action.
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